[HTML][HTML] Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
PF Ferrucci, J Pigozzo, M Maio, GCA Cappellini… - Annals of …, 2016 - Elsevier
Background Clinical responses to ipilimumab are variable in terms of onset, magnitude and
duration. Upfront identification of patients who are more likely or unlikely to benefit from …
duration. Upfront identification of patients who are more likely or unlikely to benefit from …
[引用][C] Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
P Ferrucci, P Ascierto, J Pigozzo… - ANNALS OF …, 2016 - research.unipg.it
[引用][C] Baseline neutrophils and derived neutrophilto-lymphocyte ratio: Prognostic relevance in metastatic melanoma patients receiving ipilimumab
PF Ferrucci, PA Ascierto, J Pigozzo… - ANNALS OF …, 2016 - iris.uniupo.it
Baseline neutrophils and derived neutrophilto-lymphocyte ratio: Prognostic relevance in metastatic melanoma patients receiving ipilimumab
PF Ferrucci, PA Ascierto, J Pigozzo… - Annals of …, 2016 - research.uniupo.it
Background: Clinical responses to ipilimumab are variable in terms of onset, magnitude and
duration. Upfront identification of patients who are more likely or unlikely to benefit from …
duration. Upfront identification of patients who are more likely or unlikely to benefit from …
[引用][C] Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
PF Ferrucci, PA Ascierto, J Pigozzo, M Del Vecchio… - Annals of …, 2016 - cir.nii.ac.jp
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in
metastatic melanoma patients receiving ipilimumab | CiNii Research CiNii 国立情報学研究所 …
metastatic melanoma patients receiving ipilimumab | CiNii Research CiNii 国立情報学研究所 …
[PDF][PDF] Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
PF Ferrucci, PA Ascierto, J Pigozzo… - Annals of …, 2016 - researchgate.net
Background: Clinical responses to ipilimumab are variable in terms of onset, magnitude and
duration. Upfront identification of patients who are more likely or unlikely to benefit from …
duration. Upfront identification of patients who are more likely or unlikely to benefit from …
Baseline neutrophils and derived neutrophilto-lymphocyte ratio: Prognostic relevance in metastatic melanoma patients receiving ipilimumab
PF Ferrucci, PA Ascierto, J Pigozzo… - ANNALS OF …, 2016 - usiena-air.unisi.it
Baseline neutrophil and derived neutrophil-to-lymphocyte ratio, either alone, or better
combined, are significantly and independently associated with progression-free survival and …
combined, are significantly and independently associated with progression-free survival and …
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
PF Ferrucci, PA Ascierto, J Pigozzo… - Annals of oncology …, 2016 - pubmed.ncbi.nlm.nih.gov
Background Clinical responses to ipilimumab are variable in terms of onset, magnitude and
duration. Upfront identification of patients who are more likely or unlikely to benefit from …
duration. Upfront identification of patients who are more likely or unlikely to benefit from …
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
PF Ferrucci, PA Ascierto, J Pigozzo… - Annals of …, 2016 - hero.epa.gov
BACKGROUND: Clinical responses to ipilimumab are variable in terms of onset, magnitude
and duration. Upfront identification of patients who are more likely or unlikely to benefit from …
and duration. Upfront identification of patients who are more likely or unlikely to benefit from …
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab.
PF Ferrucci, PA Ascierto, J Pigozzo… - Annals of Oncology …, 2016 - europepmc.org
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in
metastatic melanoma patients receiving ipilimumab. - Abstract - Europe PMC Sign in | Create an …
metastatic melanoma patients receiving ipilimumab. - Abstract - Europe PMC Sign in | Create an …